Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin Price-Fixing $242 Mil. Class Settlement Fund Approved

This article was originally published in The Tan Sheet

Executive Summary

A Washington, D.C. federal judge on March 28 gave final approval to a vitamin price-fixing class action settlement that is less than one-quarter the amount and scope originally announced due to the number of large companies opting out.
Advertisement

Related Content

Vitamin price-fixing
Vitamin price-fixing
Vitamin price-fixing
Perrigo Multiple Acquisitions Expected In Next 12 Months - CEO Gibbons
Vitamin Price-Fixing $335 Mil. Settlement Reached For Indirect Purchasers
Vitamin Class Settlement Opt-Outs Cannot Intervene - Appeals Court
Vitamin Firms, Execs Agree To Price-Fixing Guilty Pleas, $33 Mil. Fines
BASF, Hoffmann-La Roche Execs Plead Guilty To Vitamin Conspiracy Charges
Vitamin Price-Fixing Settlement Opt-Outs Include Supplement Leaders
Vitamin Price-Fixing Settlement Opt-Outs Include Supplement Leaders

Topics

Advertisement
UsernamePublicRestriction

Register

PS091048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel